Evidence map›Paper›PMID 38585839›Full record

ArticleResearch square2024

Androgen loss weakens anti-tumor immunity and accelerates brain tumor growth.

Juyeun Lee, Yoon-Mi Chung, Lee Curtin, Daniel J Silver, Yue Hao, Cathy Li, Josephine Volovetz, Ellen S Hong, Jakub Jarmula, Sabrina Z Wang and 6 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Juyeun LeeDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Yoon-Mi ChungDesai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, FL, USA.
Lee CurtinMayo Clinic, Mathematical NeuroOncology Lab, Precision Neurotherapeutics Innovation Program, Mayo Clinic, AZ, USA.
Daniel J SilverDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-7085-2626
Yue HaoTGen, Translational Genomics Research Institute, Phoenix, AZ, USA.
Cathy LiDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Josephine VolovetzDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Ellen S HongDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Jakub JarmulaDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Sabrina Z WangDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Kristen E KayDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Michael BerensDepartment of Neurosurgery, Mayo Clinic, AZ, USA.ORCID 0000-0002-3382-6787
Michael NicosiaDepartment of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Kristin R SwansonSylvester Comprehensive Cancer Center, University of Miami.ORCID 0000-0002-2464-6119
Nima SharifiDesai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, FL, USA.
Justin D LathiaDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0003-3168-7290
Cleveland Clinic · USTranslational Genomics Research Institute · USUniversity of Miami · USWinnMed · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
Sex-specific differences in the tumor microenvironment alter glioblastoma growthP01CA245705 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI Justin D. Lathia · 2020 to 2026
$15.0M
Outreach CoreU54CA274504 · NCI · MAYO CLINIC ARIZONA · PI Kristin R Swanson · 2023 to 2026
$8.6M
Elucidating a novel molecular biomarker for castration-resistant prostate cancerR01CA172382 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Nima Sharifi · 2012 to 2026
$5.2M
Medical Scientist Training Program at Case Western Reserve UniversityT32GM152319 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI Heather Broihier, Alex Yee-Chen Huang · 2024 to 2026
$5.1M
Langworthy Diversity Supplement: Image-based models of tumor-immune dynamics in glioblastomaU01CA250481 · NCI · MAYO CLINIC ARIZONA · PI CANOLL, PETER, HU, LELAND · 2021 to 2025
$3.8M
Contribution of Myeloid-Derived Suppressor Cells to Neuro-Inflammatory Alterations and Disease Progression in GlioblastomaR35NS127083 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI Justin D. Lathia · 2022 to 2026
$3.1M
Aberrant tumor metabolism that enables AR antagonist-resistant prostate cancerR01CA236780 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SHARIFI, NIMA · 2020 to 2024
$1.8M
CYP17A1-independent androgen synthesis and prostate cancer resistance to next-generation hormonal therapyR01CA261995 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Nima Sharifi · 2022 to 2026
$1.8M
Polyamines drive glioblastoma progressionF31CA264849 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI KAY, KRISTEN · 2021 to 2023
$108k
NCI NIH HHS F31 CA264849NCI NIH HHS P01 CA245705NCI NIH HHS R01 CA172382NCI NIH HHS R01 CA236780NCI NIH HHS R01 CA261995NCI NIH HHS U01 CA250481NCI NIH HHS U54 CA274504NIGMS NIH HHS T32 GM007250NIGMS NIH HHS T32 GM152319NINDS NIH HHS R35 NS127083
6 · The paper itself

Abstract

Many cancers, including glioblastoma (GBM), have a male-biased sex difference in incidence and outcome. The underlying reasons for this sex bias are unclear but likely involve differences in tumor cell state and immune response. This effect is further amplified by sex hormones, including androgens, which have been shown to inhibit anti-tumor T cell immunity. Here, we show that androgens drive anti-tumor immunity in brain tumors, in contrast to its effect in other tumor types. Upon castration, tumor growth was accelerated with attenuated T cell function in GBM and brain tumor models, but the opposite was observed when tumors were located outside the brain. Activity of the hypothalamus-pituitary-adrenal gland (HPA) axis was increased in castrated mice, particularly in those with brain tumors. Blockade of glucocorticoid receptors reversed the accelerated tumor growth in castrated mice, indicating that the effect of castration was mediated by elevated glucocorticoid signaling. Furthermore, this mechanism was not GBM specific, but brain specific, as hyperactivation of the HPA axis was observed with intracranial implantation of non-GBM tumors in the brain. Together, our findings establish that brain tumors drive distinct endocrine-mediated mechanisms in the androgen-deprived setting and highlight the importance of organ-specific effects on anti-tumor immunity.

Identifiers

PMID38585839
PMCPMC10996802
OpenAlexW4393314545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.